FDA declines to extend nitrosamine risk assessment deadline
Regulatory NewsJoanne S. Eglovitch
ComplianceNorth AmericaPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchComplianceNorth AmericaPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/Policy